Epstein-Barr virus BamHI-A rightward reading frame 1-derived peptide–Major Histocompatibility Complex (EBV BARF1-pMHC)

Epstein-Barr virus (EBV) BARF1-derived peptide–MHC complexes are molecular targets formed when fragments of the BARF1 protein are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, typically HLA-A*02:01 (Seto et al., 2005, Journal of Virology). The BARF1 gene is an EBV-encoded early gene that functions as a soluble decoy receptor for colony-stimulating factor 1 (CSF-1), thereby inhibiting macrophage activation and modulating the host immune response (Tarakanova et al., 2007, Journal of Virology). In EBV-associated malignancies such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric cancer (EBV-GC), BARF1 is consistently expressed during the restricted latency phase, making these pMHC complexes highly specific markers for malignant cells (Zheng et al., 2007, Journal of Cancer Research and Clinical Oncology). Therapeutic strategies targeting these complexes involve the use of adoptive cell therapies, such as T-cell receptor (TCR) engineered T-cells, or TCR-like antibodies that mimic the specificity of the immune system to recognize intracellular antigens presented on the surface (Sim et al., 2013, Cancer Gene Therapy). Because BARF1 is a viral protein with no human homolog, these complexes offer a significant therapeutic window with reduced risk of systemic toxicity compared to traditional chemotherapy. Research continues to focus on identifying the most immunogenic BARF1 epitopes to improve the efficacy of TCR-T therapies in treating refractory EBV-positive tumors.

Other names

BARF1 peptide-HLA complexEBV BARF1-MHC complexBARF1-derived epitope-MHCBARF1-pMHCHLA-restricted BARF1 antigen

Targeting of peptide-MHC complexes by engineered T-cell receptors (TCRs) or TCR-like antibodies to induce selective lysis of EBV-infected or malignant cells through granzyme/perforin-mediated apoptosis or antibody-dependent cellular cytotoxicity.